The Scary Future of Rare Disease Management

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug interventions that do not meaningfully benefit their covered lives. Rare disease therapies, often viewed as attractive areas for pharmaceutical & biotech manufacturers, represent some of the most expensive interventions available today given inherently limited competition. Yet, as more manufacturers enter … Continued

Three Pathways have emerged in Innovative Access Agreements

The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors … Continued

Outcomes Based Agreements

The days of simply determining the market demand for a new drug as a function of price and choosing the revenue or profit optimizing point are gone. In our new environment, an explicit rationale, the “value-based price” has become a prerequisite for enabling conversation with payers while policy-makers seem poised to limit the pricing corridors … Continued

SNDS: A Goldmine for Effective Decision Making?

Real-World Data (RWD) have been increasingly used to further understand the natural history of a disease or condition, treatment patterns in RW practice, as well as the effectiveness, safety and costs associated with treatment options. They help exploring research questions, potentially complement clinical trial findings, and fill knowledge gaps. Different existing data sources can be … Continued

Stakeholder perspectives: current and potential benefits

Amongst the real world data sources in Europe, the French Healthcare database SNDS is the largest and potentially the most comprehensive healthcare data resource, covering ~65 million lives, more than 99% of the French population and about 10% of Europe. Watch this short video by Nadia Quignot, Director, Decision Analytics & Real World Evidence at … Continued

1 of 4
Back to top
Powered by Translations.com GlobalLink OneLink Software